This profile describes access and programme structure. Inclusion is not an endorsement, regulatory finding, or clinical recommendation. Prescription decisions belong to a qualified prescriber.
At a glance
Pricing, medicine, location, care, fulfilment, funding, and policy claims are separated below.
An open check means the public sources were not specific enough—not that the service failed the check.
Resumen en español
Remedy Meds para usuarios hispanohablantes
Esta sección ofrece una orientación breve en español sobre el perfil estadounidense. La investigación completa de precios, acceso, farmacia y seguimiento permanece arriba mientras ampliamos la revisión editorial en español.
No encontramos una fuente primaria suficientemente específica para afirmar que una cita clínica esté disponible en español. Confirma el idioma y cualquier servicio de interpretación antes de pagar.
- si la cita concreta será en español;
- el coste mensual ordinario y qué incluye;
- la licencia estatal del profesional;
- el medicamento, la farmacia y el coste por separado.
Esta traducción editorial no demuestra que el proveedor ofrezca atención clínica en español y no sustituye una valoración médica.
Comparar proveedores para hispanohablantes en EE. UU. →How the program is structured
A cash-only, medication-inclusive program with compounded semaglutide, compounded tirzepatide, and microdose paths, unlimited clinician access, monthly refill forms, and 28-day shipments. The public “cancel anytime” message is bounded by a 48-hour non-renewal cutoff and generally nonrefundable paid terms.
GLP.directory checked the cited public sources on Sep 13, 2026. We reviewed published access, cost, care, fulfilment, funding, cancellation, monitoring, and switching details; we have not audited individual clinical encounters, prescriptions, pharmacy operations, or outcomes.
Availability can change by state, clinician, medical history, product, pharmacy, inventory, and insurance plan. “Not publicly confirmed” means we did not find a sufficiently specific answer in the cited public material. Confirm the current patient-specific answer before paying or changing care.
Service configuration
These structured fields power the directory filters. They describe the reviewed public route and should be reconfirmed for the selected plan.
- Provider type
- Telehealth program
- Medicine context
- Semaglutide (Wegovy; Ozempic/Rybelsus for type 2 diabetes) · Tirzepatide (Zepbound; Mounjaro for type 2 diabetes)
- Formats reviewed
- Injection
- Funding routes
- Private pay
- Service features
- Clinician support · Switching pathway · Home delivery
- Access check
- Provider coverage published; confirm treatment
- Evidence status
- Primary sources reviewed
- Research depth
- 2 cited sources · 4 medicine rows · 4 open checks
Recurring cost breakdown
- The checkout sets an upfront subscription-term fee.
- That fee includes platform access, clinician consultations, a prescription if eligible, four weeks of compounded medication, and shipping.
- Charges continue even if the member does not complete a refill form and therefore receives no shipment in that period.
- Additional clinician-requested services or lab testing can be outside the membership.
- Medicine + dose
- Membership or consultation
- Delivery + supplies
- Labs + follow-up
- Renewal after offers
Medication and formulation matrix
| Medication | Form | Regulatory / program path | Published price view |
|---|---|---|---|
| Compounded semaglutide | Weekly injection | Not FDA-approved | Included in checkout subscription fee |
| Compounded tirzepatide | Weekly injection | Not FDA-approved | Included in checkout subscription fee |
| Microdose GLP-1 | Split twice weekly as advertised | Compounded; not FDA-approved | Checkout-specific; excluded from warranty |
| Ozempic / Zepbound | Brand injection | Retail brand route | Retail pricing; warranty excluded |
Important: “Compounded” means the product is not FDA approved. A brand approved for one condition is not automatically approved for another. The treating clinician determines whether any prescription is appropriate.
State-by-state availability
- The June 2026 terms state availability in all 50 states and D.C.
- A particular product, synchronous visit, or pharmacy can still depend on state and clinician judgment.
Clinician access and follow-up cadence
- Initial synchronous clinician review is described.
- Refill reviews may be asynchronous unless the patient asks for or the clinician requires a synchronous session.
- Standard-dose members complete a refill form approximately every four weeks; microdose members every three months.
- Unlimited video calls and messaging are advertised.
Pharmacy and fulfillment
- The site says medication ships from licensed US compounding pharmacies, generally within 48 hours, in 28-day supplies.
- The public pages do not name the dispensing pharmacy for each state.
- Terms require 13 shipments over 12 months for the weight-loss warranty.
Insurance and prior authorization
- The terms state that Remedy is cash pay only and does not accept insurance.
- HSA/FSA acceptance is advertised, subject to account rules.
Cancellation, refund, and commitment
- Cancellation stops the next term only when notice is given at least 48 hours before renewal.
- The current paid subscription term is generally nonrefundable and service continues to its end.
- The 365-day warranty has extensive eligibility conditions: continuous 12-month enrollment, eligible standard-dose compounded medication, 13 shipments, adherence, no outside weight-loss medication, and a timely claim.
Labs, monitoring, and dose management
- Labs are not universally included and may be required as an additional service.
- Monthly refill reporting is the principal published monitoring cadence for standard-dose plans.
Maintenance and switching
- Dose changes are clinician-directed; existing treatment does not guarantee an identical starting dose.
- Any enrollment lapse or pause voids the advertised 12-month warranty, which matters for a later switch.
Program snapshot
All-in cash-pay program
Profiled support: Ongoing clinician access, Simplified intake and fulfillment.
Cash pay
The reviewed model is cash pay.
Verify before purchase
Request the dispensing pharmacy, formulation, beyond-use date, and cold-chain procedure.
What the advertised program may include
- Online assessment
- Licensed clinician review
- Medication when prescribed
- Shipping as advertised
Useful comparison signals
Based on the provider’s published program structure, this profile is tagged for the following searches. These are filters, not endorsements or clinical recommendations.
- Starting care and comparing first-provider requirements
- Switching providers or continuing an established treatment
- Comparing lower-cost access routes and recurring totals
- Ongoing clinician access
- Simplified intake and fulfillment
Open evidence gaps
These are material details we could not confirm precisely enough from the cited public pages. They are the highest-priority questions to resolve directly.
- Named pharmacy by state
- Exact public price before checkout
- Routine lab criteria
- Response-time guarantee for clinical messages
Questions to ask before paying
- What is the ordinary recurring total after any introductory period?
- Does that total include clinician care, medication, supplies, labs, and shipping?
- Which clinician group and dispensing pharmacy will be responsible for my care?
- What happens to billing if I am not prescribed the advertised treatment?
- What records and timing do you require if I am switching from another provider?
Source ledger
Every entry below is a provider-controlled or official public source. A source link documents what was published; it does not independently validate performance, regulatory compliance, safety, or outcomes.
Treatments, clinical access, 28-day fulfillment and public program claims
All-state access, included services, billing, cancellation, refill cadence and warranty rules